12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersStoke Therapeutics (NASDAQ:STOK) shares increased by 46.1% to $15.03 during Wednesday's regular session. The company's market cap stands at $671.1 million. As per the press release, Q4 earnings
BenzingaMar 27 12:31 ET
Top Premarket Gainers
MicroAlgo (MLGO) stock rose 52% in recent Monday premarket activity, recovering from moderate losses on Friday. Salarius Pharmaceuticals (SLRX) shares surged 24% after reporting Friday a narrower Q4 n
MT NewswiresMar 25 07:50 ET
Dada Nexus, Salarius Pharmaceuticals And 3 Stocks To Watch Heading Into Monday
With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Dada Nexus Limited (NASDAQ:DADA) to report qua
BenzingaMar 25 02:50 ET
Express News | Salarius Pharmaceuticals Shares Are Trading Higher After the Company Reported Q4 Financial Results
Moomoo 24/7Mar 22 16:10 ET
Express News | Salarius Pharmaceuticals Q4 2023 GAAP EPS $(0.22) Beats $(1.01) Estimate
Moomoo 24/7Mar 22 16:07 ET
Salarius Pharmaceuticals Sees Funding Sufficient Into 1H25 >SLRX
Salarius Pharmaceuticals Sees Funding Sufficient Into 1H25 >SLRX
Dow JonesMar 22 16:06 ET
Press Release: Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Patient Enrollment Resumed in the Investigator-initiated Phase 1/2 Clinical Trial of
Dow JonesMar 22 16:05 ET
Salarius Pharmaceuticals 4Q Loss/Shr 22c >SLRX
Salarius Pharmaceuticals 4Q Loss/Shr 22c >SLRX
Dow JonesMar 22 16:05 ET
Salarius Pharmaceuticals Announces Executive Restructuring and Cost-Saving Measures
TipRanksFeb 23 06:13 ET
Salarius Pharmaceuticals Implements Cost-savings Measures
RTTNewsFeb 22 08:42 ET
Salarius's CEO David Arthur Steps Down
Seeking AlphaFeb 22 08:14 ET
Press Release: Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses Company implementing a series of cost-savings measures desi
Dow JonesFeb 22 08:00 ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersKiora Pharmaceuticals (NASDAQ:KPRX) stock rose 48.3% to $0.82 during Thursday's pre-market session. The company's market cap stands at $6.2 million. Salarius Pharmaceuticals (NASDAQ:SLRX) stock
BenzingaFeb 1 08:06 ET
Salarius Pharmaceuticals Issued U.S. Patent No. 11,773,080 Titled "Deuterium-Enriched Isoindolinonyl-Azepanediones And Related Compounds And Methods Of Treating Medical Disorders Using Same"
Expands IP portfolio with composition-of-matter protection into 2039 for novel molecular gluesProtein degrader portfolio now includes 17 issued patents across six patent families
BenzingaJan 16 08:16 ET
Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders
Expands IP portfolio with composition-of-matter protection into 2039 for novel molecular glues Protein degrader portfolio now includes 17 issued patents across six patent families HOUSTON, Jan. 16, 2
GlobeNewswireJan 16 08:00 ET
Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination With Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment
HOUSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) announces that the hematologic cancer Phase 1/2 clinical trial being conducted at the University of Texas MD Anderson Cancer
GlobeNewswireJan 3 08:30 ET
Express News | Salarius Completes FDA Type B Meeting For Seclidemstat Ewing Sarcoma Development Program
Moomoo 24/7Nov 7, 2023 08:30 ET
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersMiromatrix Medical (NASDAQ:MIRO) stock rose 223.1% to $3.36 during Monday's pre-market session. The company's market cap stands at $91.7 million. Eargo (NASDAQ:EAR) stock rose 54.16% to $2.59.
BenzingaOct 30, 2023 09:05 ET
Salarius Pharmaceuticals 13D Filing Shows Elvin Lee Reported 6.09% Stake In Co As Of 23 October 2023
Salarius Pharmaceuticals 13D Filing Shows Elvin Lee Reported 6.09% Stake In Co As Of 23 October 2023
BenzingaOct 27, 2023 16:04 ET
12 Health Care Stocks Moving In Friday's After-Market Session
GainersContraFect (NASDAQ:CFRX) stock rose 17.5% to $0.47 during Friday's after-market session. The market value of their outstanding shares is at $2.5 million. Exagen (NASDAQ:XGN) shares rose 15.63%
BenzingaOct 6, 2023 17:31 ET
No Data
No Data